matinas biopharma

At the American society for microbiology 2017 conference NIH announced interim data from phase 2a study for CMC infection.It is open label study.Two out of two patients met the primary endpoint.Need one more patient out of additional 14 patients to meet the endpoint,for the study to be successful.
when it comes to antibiotics, animal studies have been good representative of what is to come in human studies.
So far looks promising.